| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 98.720 | - | - | 40.523 | 34.890 | 25.917 | - | - | 0 |
| Total Income - EUR | - | 98.720 | - | - | 40.523 | 34.890 | 26.905 | - | - | 0 |
| Total Expenses - EUR | - | 89.874 | - | - | 38.503 | 34.489 | 32.213 | - | - | 0 |
| Gross Profit/Loss - EUR | - | 8.846 | - | - | 2.020 | 401 | -5.308 | - | - | 0 |
| Net Profit/Loss - EUR | - | 7.859 | - | - | 1.615 | 75 | -5.648 | - | - | 0 |
| Employees | - | 1 | - | - | 1 | 1 | 1 | - | - | 0 |
Check the financial reports for the company - Alexpharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 4.106 | - | - | 1.274 | 687 | 6.862 | - | - | 0 |
| Current Assets | - | 48.013 | - | - | 36.650 | 36.286 | 30.161 | - | - | 29.994 |
| Inventories | - | 0 | - | - | 0 | 0 | 0 | - | - | 0 |
| Receivables | - | 41.930 | - | - | 30.483 | 32.503 | 21.561 | - | - | 21.442 |
| Cash | - | 6.083 | - | - | 6.167 | 3.783 | 8.599 | - | - | 8.552 |
| Shareholders Funds | - | 47.730 | - | - | 34.857 | 34.271 | 27.863 | - | - | 20.885 |
| Social Capital | - | 423 | - | - | 400 | 393 | 384 | - | - | 382 |
| Debts | - | 4.389 | - | - | 3.067 | 2.702 | 9.159 | - | - | 9.109 |
| Income in Advance | - | 0 | - | - | 0 | 0 | 0 | - | - | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "5520 - 5520" | |||||||||
| CAEN Financial Year |
5520
|
|||||||||
Comments - Alexpharm S.r.l.